Company: RGNT
Filing Date: 2025-02-12
Form Type: DRS/A
Source: 0001213900-25-012299
Chunk: 190

Company: REGENTIS BIOMATERIALS LTD.
Filing Date: 2025-02-12
Form: DRS/A
Chunk 190
---
 the Interest Amount (each as defined therein) shall be automatically converted
into 221,456 Ordinary Shares.

Other Financings

Between October 2024 and November 2024, we entered into bridge loan agreements, or the Bridge Loans, pursuant to which we obtained a bridge loan from the lenders thereto including certain related parties. The Bridge Loans shall bear interest at 8% per annum until maturity and we agreed to pay the lenders an additional risk premium equal to 30% of their respective loan amount. In October 2024, we amended the Bridge Loans pursuant to which the Bridge Loans may be extended beyond March 31, 2025 and until June 30, 2025, subject to the Registration Statement effectiveness not later than March 31, 2025 and the fulfillment of additional cumulative conditions. Furthermore, upon the occurrence of a Qualifying IPO, the Bridge Loan lenders, shall be granted warrants to purchase such number of Ordinary Shares equal to two times their respective loan amount in addition to the risk premium based on a price per share equal to 75% of the lowest price per share of the Company’ Ordinary Shares during the first five trading days following the consummation of such initial public offering. The chairman of our board of directors is a lender under one of the Bridge Loans. As of January 15, 2025, the Company received $250,000 under such Bridge Loans.

Between December 2023
and January 2024, we entered into loan agreements, or the 2024 Loan Agreements pursuant to which we obtained a loan in the aggregate
amount of $150,000 from the lenders thereto including certain related parties. In October 2024, we amended the 2024 Loan Agreements
pursuant to which the 2024 Loan Agreements have been extended until August 31, 2025, shall bear interest at 8% per annum until
maturity commencing as of September 1, 2024 and we agreed to pay the lenders at maturity an additional aggregate amount of $50,000
as a risk premium. Furthermore, upon the occurrence of a Qualifying IPO, the 2024 Loan Agreements lenders, shall be granted warrants
to purchase such number of Ordinary Shares equal to two times their respective loan amount in addition to a risk premium based on a
price per share equal to 75% of the lowest price per share of the Company’ Ordinary Shares during the first five trading days
following the consummation of such initial